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SUMMARY: Identification of new biomarkers to distinguish between viral and bacterial 
pneumonia. These markers could provide the basis for a rapid diagnostic for field-based 



















Differential etiologies of pediatric acute febrile respiratory illness pose challenges for all 
populations globally but especially in malaria-endemic settings because the pathogens 
responsible overlap in clinical presentation and frequently occur together. Rapid 
identification of bacterial pneumonia with high quality diagnostic tools would enable 
appropriate, point of care antibiotic treatment. Current diagnostics are insufficient, and the 
discovery and development of new tools is needed.  We report a unique biomarker 
signature identified in blood samples to accomplish this.   
METHODS:  
Blood samples from 195 pediatric Mozambican patients with clinical pneumonia were 
analyzed with an aptamer-based, high dynamic range, quantitative assay (~1200 proteins). 
We identified new biomarkers using a training set of samples from patients with established 
bacterial, viral, or malarial pneumonia. Proteins with significantly variable abundance across 
etiologies (FDR<0.01) formed the basis for predictive diagnostic models derived from 
machine learning techniques (Random Forest, Elastic Net). Validation on a dedicated test set 
of samples was performed.  
RESULTS:  
Significantly different abundances between bacterial and viral infections (219 proteins) and 
bacterial infections and mixed (viral and malaria) infections (151 proteins) were found. 
Predictive models achieved >90% sensitivity and >80% specificity, regardless of number of 
















particular degranulation including HP, LCN2, LTF, MPO, MMP8, PGLYRP1, RETN, SERPINA1, 
S100A9, and SLPI.  
CONCLUSION: 
Blood protein signatures highly associated with neutrophil biology reliably differentiated 
bacterial pneumonia from other causes. With appropriate technology, these markers could 
provide the basis for a rapid diagnostic for field-based triage for antibiotic treatment of 
pediatric pneumonia.  




















Pediatric febrile respiratory illness is a leading cause of mortality and morbidity globally. 
Identifying the etiology — bacterial1, viral, or (less commonly) malaria2,3 — is crucially 
important but difficult due to similar clinical presentations. The critical need globally is to 
identify bacterial infections3, so they can be treated appropriately and reduce mortality.4,5  
Rapid bacterial diagnosis is challenged by current diagnostic tests: laborious microbiological 
culture or molecular testing methods, if available, often lack sensitivity to detect bacterial 
pathogens6 as do radiological evaluations (through chest-X-ray or ultrasound) with equal 
limitation in availability. Malaria or viral infections and bacterial secondary co-infections 
occur commonly together, increasing the challenge of a specific, treatable diagnosis.7,8  
Host cellular responses to bacterial, viral, and malaria infections are distinct, being chiefly 
neutrophilic, lymphocytic, or monocytic, respectively, and represent prime targets as 
diagnostic indicators. To date, these approaches are not sufficiently reliable9–13, based on a 
recommended benchmark14 of thresholds for sensitivity (desirable ≥95%, acceptable 
≥90%) and specificity (≥90% and ≥80%). We hypothesized that the distinctive cellular host 
responses could be detected at the protein level. We test this hypothesis based on the 
differential expression of proteins in pediatric febrile respiratory illness blood specimens 
from southern Mozambique, where malaria is endemic. Febrile respiratory illness cases 
were classified by available gold standards, and using highly specific case-definition, to one 
of three underlying causes--bacteria, viruses, or malaria--or to a combination (“mixed 
infections”). Proteins were assayed with SOMAScan technology (Somalogic, Boulder, CO), an 
array-based modified aptamer platform covering a range of biological pathways including 
















approximately 1200 proteins simultaneously offers a high dynamic range  and has modest 
sample requirements (150 ul plasma).15  
The resulting protein expression data were used to create machine learning-based models 
for distinguishing bacterial from viral or malaria infections. The same data, along with data 
from our prior RNA- and protein-based studies9,13, provided the basis for pathway analyses, 
to help confirm the underlying biology of the host response. 
Methods 
Study Design 
The study recruited two groups of children (<10 years of age) at the Manhiça District 
Hospital in Mozambique as follows: (1) children with febrile respiratory illness admitted to 
the hospital fulfilling the “clinical pneumonia” criteria (as defined by WHO), and (2) afebrile 
and asymptomatic healthy community controls used to establish a baseline. Febrile 
respiratory illness cases were assigned by all available gold standard tests to one of three 
underlying causes, bacteria, viruses, or malaria, or to a combination (“mixed infections”). 
Study population and sample classification procedure 
Children with fever at admission (>37.5°C axillary temperature) or prior-24-hour history of 
fever meeting the WHO case definition for clinical pneumonia (increased respiratory rate 
and cough or difficulty breathing)16 were selected for the study. Informed consent was 
obtained from parents/guardians. All children underwent anteroposterior chest 
radiography; images were independently interpreted following the WHO recommended 
















Patients were classified as having clinical pneumonia associated with bacterial, malaria, or 
viral infection using the criteria described in Valim et al. (2016), with minor modifications. In 
brief, patients were classified as bacterial pneumonia when pathogenic bacteria were 
isolated (or detected through RT-PCR) from blood or pleural exudate, and after confirming 
the absence of malarial infection. Viral pneumonia required the detection in the 
nasopharyngeal aspirate (NPA) of a viral respiratory pathogen, no isolated bacteria in the 
blood culture or RT-PCR, no “endpoint pneumonia” in the chest X-ray, and negative malaria 
microscopy. Finally, a malaria case required a positive malaria smear microscopy (according 
to predetermined parasitemia thresholds in relation to age18), normal chest X-ray and no 
detectable bacterial infection. We analyzed our case definitions against ALMANACH criteria 
(supplemental material and Table S7).  
To address the known insensitivity of blood culture for bacterial pneumonia, cases were also 
assigned a bacterial etiology if the NPA was negative for virus but the patient had 
leukocytosis and a dense radiographic consolidation (endpoint pneumonia) based on 
consensus of two independent experts. Since NPAs are often positive on RT-PCR for 
potential viral respiratory pathogens even in clinically well children, the detection of a virus 
in the nasopharyngeal aspirate did not alter the class assignments for confirmed bacterial or 
malarial cases. See Fig. S1 for a comprehensive flowchart for patient classification. 
In addition, patient samples with mixed infections were also included in the study (for 
details see Table S3). “Virus & probable bacterial secondary co-infection” samples were 
virus positive, culture and PCR-negative for bacteria but with leukocytosis and radiographic 
















SOMAScan protein assay 
The SOMAScan assay uses SOMAmers (Slow Off-rate Modified Aptamers) to capture 
proteins and translates binding events into signals measured in Relative Fluorescence Units 
(RFU). RFU are directly proportional to target protein abundance in the sample, calculated 
by a standard curve generated for each protein-SOMAmer pair. The dynamic range is 
enhanced by three serial dilutions, with the least concentrated dilution used to quantify the 
most abundant proteins (~μM concentration in the original sample), and the most 
concentrated used for the least abundant proteins (fM to pM concentration).15 Samples 
were assayed in two batches (15 samples replicated to verify consistency); the SOMAScan 
assays used in the first set of 167 samples quantified 1129 proteins and the SOMAScan 
assay used in the second set of 49 samples quantified 1279 proteins. In the two batches, 
96.4% (161/167) and 100% (49/49) of samples passed Somalogic normalization acceptance 
criteria. 
We use Somalogic protein marker labels throughout this manuscript (supplementary data 
file S1 provides full protein names). 
Protein marker selection and predictive model building 
Selection was based on statistical significance of differences in marker abundance between 
the bacteria versus virus (BvV) and bacteria versus malaria or virus (BvVM) comparisons. 
Classifiers discriminated (1) BvV and (2) BvVM using the 219 and 151 statistically significant 
(FDR<0.01) markers, respectively, and their corresponding surrogates. Using optimal subsets 
of N protein markers (N=5, 10, 15, 25, 50, 100) identified using genetic algorithms, 2-class 
















results with high sensitivity and specificity with a small subset  of markers (see Fig. 1; details 
in the “Data Analysis Pipeline” in the Supplementary Appendix and Fig. S3). 
Biological processes and pathways 
To better understand the biological significance of the differentially expressed proteins, 
differential markers were used as input to the Metascape Gene Annotation and Analysis 
Resource (http://metascape.org) to query multiple ontology resources including KEGG 
pathway, Gene Ontology (GO) Biological Processes, Reactome Gene Sets, Canonical 
Pathways, and CORUM. Both three-way (Bacteria vs Malaria vs Virus) and binary (BvV) 
comparisons were explored (see Supplementary Appendix for details). 
Comparative marker analysis between technologies 
To assess whether markers identified as indicating b cterial infection were consistent across 
technology platforms, extensive comparisons were made between this and two previous 
marker studies of the same patients (RNA-sequencing and multiplex bead-based protein 
immunoassays); both studied different but overlapping samples within the same study 
population (see details in the Supplementary Appendix). 
Results  
Patient characteristics  
Between July 2010 and November 2014, 576 patients were recruited as inpatients, along 
with 117 community controls. 195 patients under 10 years of age with acute febrile 
respiratory illness met the stringent inclusion criteria and were included in this analysis. To 
















characterized as having bacterial (69 patients), malaria (42 patients), viral (48 patients), or 
mixed (23 patients) infections (for details see Table S3). 13 healthy subjects were included 
as controls. The classification scheme was similar as previously described (see Fig. S1 for a 
patient classification flowchart).9,13 No significant differences in age, sex, weight, height, 
nutritional status, or duration of hospital admission were observed between bacterial, viral, 
and malaria sample sets. (See Table 1 and Table S1 for patient demographic and disease 
characteristics). Case fatality rates were high (6%) for the bacterial group, but none of the 
malaria cases or viral cases died. Malnutrition was highly prevalent among the three groups, 
and HIV prevalence was also high, although significantly higher among the bacterial group. 
Bacterial cases had the highest leukocyte count and respiratory rates. Malaria cases were 
most anemic, had the highest mean axillary temperature, and had the lowest respiratory 
rates. Viral cases had the lowest leukocyte count, had lower mean axillary temperature and 
were less anemic. Neutrophil levels were statistically higher for the bacterial etiology, but 
the overlap between etiologies was too great for this to serve as a classifier. 
From the 195 patients, 210 peripheral blood samples (including 15 replicates, four of which 
were excluded from downstream analysis) were assayed for protein composition using the 
SOMAScan platform (see Fig. 1). Sample characteristics and designations of single (167 
samples) and mixed infections with controls (39 samples) can be found in Table S2 and S3, 
respectively.  
Differential markers 
Using the SOMAScan data, 219 and 151 differentially expressed protein markers (FDR<0.01) 
were identified in the BvV comparison (Table S4 A, heatmap in Fig. 2) and the BvVM 
















expression signatures determined by SOMAscan are shown in the heatmap in Fig. 2 A. This 
signal is manifest only after marker selection; unsupervised clustering in the space of the 
entire 1107 protein panel does not reveal a clear dominant structure related to infectious 
etiology (Fig. S2 A). Box and whisker plots of the 100 top ranked markers are depicted in Fig. 
S4. 
Performance of predictive diagnostic models 
Our chief aim was to develop a protein-based biomarker panel to distinguish bacterial from 
other etiologies of clinical pneumonia with accuracy which would support clinical decision-
making. RF and EN models had generally similar performance, with RF models performing 
slightly better overall (see Table S5 C and D) and declining in performance more smoothly 
with fewer input markers. We therefore focused subsequent analyses on RF results. 
In single etiology samples, performance of the BvV model (evaluated on the held-aside 
validation samples) was excellent. Sensitivity and specificity for bacterial cases using all 219 
markers were 90% and 100%, respectively meeting the Foundation for Innovative New 
Diagnostics (FIND) proposed criteria for a diagnostic test of these characteristics.14 
Furthermore, sensitivity and specificity remained at 90% and 85% with only 5 markers, 
potentially simplifying the translation to a field deployable diagnostic. Accuracy was 94% 
(95% CI 0.79, 0.99) and 88% (95% CI (0.71, 0.96)), with 219 and 5 markers, respectively 
(Table 2 A and Table S5 A). 
The BvVM RF model had an accuracy of 87% (95% CI (0.74, 0.95), a specificity of 100% and a 
sensitivity of 68%. When decreasing the panel size to only 5 markers, accuracy decreased to 
















On healthy controls and mixed infection samples, the BvV RF model performed well with 
95% sensitivity, 84% specificity, and 90% accuracy (95% CI (0.76, 0.97)) (Table 2 B). The 
model correctly predicted the majority of bacterial infections and bacterial co-infections, 
successfully distinguishing these from non-bacterial infections (malaria and/or virus). Table 
S6 depicts BvV and BvVM RF model statistics on mixed infection samples without controls. 
To compare, we found that the clinical ALMANACH models were uniformly inferior to our 
molecular predictors, with a particularly dramatic loss of specificity (see Table S7 for 
details). 
Genetic algorithm-derived and surrogate markers 
Marker subsets (with N ranging from 5 to 100 markers) were selected using genetic 
algorithms. Since the results can be nondeterministic, the method was re-run multiple 
times. Across all runs of the genetic algorithm, IL1RL1, HMGB1, PDCD1LG2, ROBO2, and 
PAPPA were the five protein markers most often selected. For the BvVM models, the most-
selected markers were LTA.LTB1 (Lymphotoxin alpha2/beta1 protein), TPI1, SERPINA1, 
IGFBP2, and ROR1 (see supplementary data file S2 for complete marker lists). 
We next assessed whether models were robust to replacement of individual markers by 
corresponding surrogates. This provides an index of model stability and has practical 
relevance when converting predictive models into diagnostics, which may require marker 
substitution for technical reasons. The RF (and EN) classifiers for both BvV and BvVM proved 
to be robust to the choice of specific markers: classifier accuracy did not significantly decline 

















Biological processes and pathway analysis  
To gain insight into the biology underlying the markers of bacterial and viral infection, 
multiple databases were queried for functional and pathway annotations. Terms 
significantly enriched in the bacterial or viral pneumonia marker sets were automatically 
clustered into non-redundant groups (details in methods). Marker support for terms is 
shown in Fig. 3 A and the top twenty clusters in Fig. 3 B. Individual terms (and therefore 
clusters) could be supported by both bacterial and viral markers. Most clusters had support 
from both etiologies, but a subset (blue or red circles in Fig. 3) was strongly associated with 
a single etiology. Two GO clusters, chemotaxis and regulation of neurogenesis, were driven 
almost exclusively by viral markers, while response to bacterium (our top ranked GO term 
with 39 gene hits), regulated exocytosis, antimicrobial humoral response, positive regulation 
of response to external stimulus, and signaling by interleukins were driven almost exclusively 
by bacterial markers.  
Neutrophil-related biological processes emerged as a key biological theme associated with 
bacterial infection. In particular, the regulated exocytosis GO cluster (34 gene hits) is mostly 
neutrophil- or leukocyte-related terms. Within the top 36 GO clusters (out of 1388 total 
clusters, ranked by p value), six highly significant clusters consisting of 14 to 26 gene hits 
each were identified as neutrophil processes (migration, mediated-immunity, activation, 
degranulation, activation involved in immune response, and chemotaxis). Notably, no other 
cell type or subpopulation besides neutrophils appeared within the first 243 rank-ordered 
GO clusters. The neutrophil degranulation cluster was particularly prominent in markers that 
















that emerged from that cross-platform comparison (Fig. 3 B, D & E). This was further 
demonstrated by three-way enrichment heatmap comparisons (Fig. S9). 
Comparisons between datasets and technologies 
To assess the consistency of the results, we compared gene marker sets from similar 
marker-focused studies of the same population using different technologies. First, the 
current BvVM marker set was compared with markers found in our previously published 
RNA-sequencing approach.9 Of the 1107 proteins included in our SOMAScan assay, 78 were 
represented by genes from the set of 600 significant differentially expressed markers in the 
RNA-sequencing analysis (of ~12,000 expressed genes) (Data file S1 D). Twenty-five of these 
78 genes (corresponding to 24 proteins) proved to be statistically significant markers in our 
comparison (Fig. S6). 
In the RNA data, 18 of those 24 proteins were markers for bacterial infection and 6 were 
markers for malaria infection. A heatmap of these markers highlights the strong class 
distinctions (Fig. S7). Haptoglobin (HP) is markedly down and hemoglobin up in malaria 
samples, but the majority of markers are elevated in bacterial samples (Fig. 3 E, and see Fig. 
S6 and Fig. S8 for details on the malaria markers). When we used the SOMAScan data for 
these 24 markers to build RF and EN models, they performed similarly to 25 protein marker 
models optimized by the genetic algorithm (Table S5 E and F), suggesting that those 24 
markers would also be good candidate markers for a diagnostic assay. 
We also compared the SOMAScan marker sets with findings from a previous protein-based 
immunoassay (the RBM multiplex immunoassay).13 Five markers were identified as 
















SERPINA1 (Fig. 3, Fig. S6). Three markers, Haptoglobin (HP), Myeloperoxidase (MPO), and 
Alpha1-Antitrypsin (SERPINA1), were identified as significant markers in all three studies 
(SOMAScan, multiplex immunoassay, and RNA-sequencing) despite the very different 
methodologies employed (Venn diagram in Fig. 3D). Two markers appear in both the 
SOMAScan and multiplex immunoassay data as likely markers for malaria infection, VCAM1 
and APCS.13  
 
Discussion  
We present diagnostic models based on aptamer-derived blood protein signatures that 
accurately discriminate bacterial from viral infections of pediatric febrile respiratory illness 
with as few as 5 protein markers (94% accuracy, 90% sensitivity, 85% specificity), 
meeting/exceeding the FIND-sponsored expert consensus guidelines on diagnostics for 
bacterial pneumonia.14 Accurate discrimination of bacterial infection from both viral and 
malaria etiologies was achieved with  25 markers.  
Because the BvV model was highly predictive, we investigated the proteins to understand 
the processes that typify bacterial and viral infections. Gene enrichment and pathway 
analyses showed neutrophil-dominated processes in bacterial infections. The consistency of 
a neutrophilic host response signature is highlighted by common signals (18 bacterial 
markers) across prior studies at both the RNA and protein level, despite model and platform 
differences (Fig. 3 E). Reinforcing this observation, a cross-platform 24 marker set, highly 
enriched for neutrophil-associated proteins (neutrophil degranulation being prominent), 
















18 bacterial markers were associated with bacterial airway inflammation, modifying, 
mitigating or augmenting neutrophil immunological responses. For example, SERPINA1 and 
SLPI are both protease inhibitors regulating neutrophil elastase activity.19–21 
Bacterial pneumonia diagnostics are a challenge globally for all countries in pediatric 
populations with a need for better diagnostics to improve antibiotic stewardship and 
mortality outcomes. The limitations of the current WHO clinical pneumonia definition were 
improved upon by our strict further criteria, laboratory testing, and consensus review to 
produce the best possible set of pneumonia cases. Our objective was to develop protein-
based predictors that could eventually be ported to a field-deployable device for 
discriminating bacterial from non-bacterial pneumonia. While larger validation studies are 
needed, this study provides strong evidence that a blood-based protein panel of limited size 
can achieve the sensitivity and specificity required to guide clinical decisions regarding 
antibiotic therapy. By identifying biologically plausible sets of markers, the groundwork for 
development of a point of care test has been established, particularly considering that some 
of these markers (haptoglobin, SERPINA1, MPO etc.) are relatively simple to measure. We 
identified surrogate proteins that can be exchanged for markers in our models without loss 
of accuracy, allowing flexibility in developing a diagnostic test. Though optimized for single 
etiology samples, our models performed well in mixed infections representing the natural 
complexity of febrile respiratory illness. Importantly, these markers seem to discriminate 
appropriately, even in the context of a high underlying malnutrition or HIV prevalence, such 
as the one in Manhiça, southern Mozambique.22,23 This is a significant benchmark, as a 
predictor must be effective across the spectrum of real-life clinical scenarios. Finally, our 
















These observations may inform marker selection in future prospective studies, and together 
with our specific models and markers may facilitate the development of the optimized 
markers for pneumonia diagnosis with the eventual transition to point-of-care tests that are 
needed to change future clinical practice, particularly for those settings where associated 
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Fig. 1 Data analysis workflow. 210 samples passed QC on the SOMAScan assay to quantify 1107 
proteins. The 171 single etiology samples were classified as malaria, virus, or bacteria and included 
12 repeats that were randomly split between the training and validation datasets; the 4 repeats that 
ended up in the validation dataset were excluded from downstream analysis. The remaining 39 
samples consisted of 16 healthy community controls and 23 samples with mixed etiology. Single 
etiology samples were divided into a training set of 120 and a validation set of 47 samples. The 
training data were used for identifying differentially expressed markers between bacteria and virus, 
or bacteria and malaria or virus samples. Genetic algorithms were used to select the best 5, 10, 15, 
25, 50, and 100 markers. Classifiers for Bacteria vs Virus (BvV) and Bacterial vs Malaria or Virus 
(BvVM) were trained using Random Forest (RF) and Elastic Net (EN) algorithms. Models were tuned 
using cross validation, and final model performance was assessed using the validation data. In order 
to contend with the situation where a marker is unavailable (e.g., due to difficulty in measuring the 
marker in a clinical setting), we determined a set of surrogate markers for each differential marker 
using information correlation, a criterion based on mutual information. We then assessed model 
performance when 10% or 20% of differential markers were substituted with their corresponding 
surrogates. 
 
Fig. 2. Heatmap of the Bacteria vs Virus model and top 10 rank-aggregated markers (A) 
Hierarchically clustered heatmap of normalized SOMAscan expression values for 219 significant 
markers (FDR<0.01) from the SOMAScan Bacteria vs Virus (BvV) comparison in the space of all single 
etiology bacterial and viral samples in this study (see Fig. S10 for full resolution with details). Top 
track: viral (yellow) and bacterial (blue) etiology. (B) Top 10 rank-ordered protein markers (highest to 
lowest, left to right) in our BvV and BvVM marker sets. CCL23 (C-C motif chemokine 23),  CSF3 
















HP (Haptoglobin), RETN (Resistin), PLA2G2A (Phospholipase A2), LCN2 (Neutrophil gelatinase-
associated lipocalin), IL1RL1 (Interleukin-1 receptor-like 1), NTN4 (Netrin-4), SERPINA1 (Alpha-1-
antitrypsin), IL6 (Interleukin-6), ITIH4 (Inter-alpha-trypsin inhibitor heavy chain H4), S100A9 (Protein 
S100-A9), KYNU (Kynureninase), SLPI (Antileukoproteinase) 
 
Fig. 3 Pathways and gene enrichment analysis with differential markers shared between this 
study, RNA-sequencing, and RBM multiplex assay studies with the same study population. (A,B,C) 
Clustered terms enriched in our bacteria vs virus 2-class comparison. Each node represents one term 
describing a biological process or pathway. Edges connect similar terms (similarity score (κ) > 0.3); 
the thickness of the edge represents the similarity score. Each term is represented by a circle node, 
where the size is proportional to the number of input markers. The underlying file can be found as 
an additional supplementary file (“Cytoscape BvV network”).  (A) Distribution of support for each 
node from bacterial (red) and viral (blue) markers, i.e. each pie sector is proportional to the number 
of hits that originated from a particular marker list. (B) Nodes colored by their membership in one of 
the top 20 clusters. Each cluster is named for the term (node) with the best p-value. Inset table: 
neutrophil degranulation, considered as a sub-pathway of regulated exocytosis, was detected as the 
major biological GO pathway shared between the BvVM marker set of this study and RNA-
sequencing data. Of the 18 bacterial markers overlapping between the studies, 10 markers are 
directly involved in neutrophil degranulation (see Fig. 3E for all 18 markers). (C) Bacteria vs Virus 
marker set with nodes colored by p-value. The darker the color, the more statistically significant the 
node (see legend for p-value ranges). (D and E) RBM and SOMAScan protein aliases were converted 
into their gene names to compare markers between studies. (D) Overlap of selected marker sets: 
SOMAScan (BvVM, n=156), RNA-Sequencing (BvVM, n=431), and RBM immunoassay (BvV and BvM, 
n=21). (E) Two direct comparisons of marker sets derived through the same approach (bacteria vs 
















specified analysis. Markers that overlapped in the two direct comparisons are depicted by filled 
circles, but not between the four individual marker sets. The color indicates the direction of 
expression change. Red:  upregulation in bacterial samples; dark blue: downregulation. Light grey: 
the marker was not detected or not included in at least one of the two marker sets. Haptoglobin 



















Table 1 Patient Demographic and Disease Characteristics at Admission  
Features on admission (signs, 




No.  Malaria No. Virus No. P† 
Age (month), mean (SD) 







Female sex, n (%) 24 (45) 69 28 (67) 42 23 (48) 48 0.07 
Clinical Examination results on 
arrival  
       
Weight (kg), mean (SD) 
10.2 (4.8) 69 
10.3 
(4.6) 
42 9 (3.4) 48 0.44 
Height (cm), mean (SD) 







MUAC (cm), mean (SD) 







Temperature (°C), mean (SD)  







Respiratory rate (cycles per min), 
mean (SD) 







Nutritional status        

















WAZ -1 SD to -3 SD, n (%) (low to 
severe underweight) 
30 (52.2) 69 
18 
(42.9) 
42 17 (35.4) 48  
WAZ < -3 SD, n (%) (severe 
underweight) 
12 (23.2)  69 
7 
(16.7) 
42 7 (14.6) 48  
WAZ: Mean (SD) 
-2 (1.8) 69 
-1.5 
(1.7) 
42 -1.5 (1.7) 48 0.09 
Anaemia status on admission         
Hemoglobin (g/dL), mean (SD) 







Hematocrit, mean (SD) 







No anaemia (HCT > 33%), n (%) 4 (6) 69 2 (5.0) 40 14 (29.2) 48  
Mild anaemia (HCT 25 - | 33%), n 
(%) 
31 (46.3) 69 
11 
(27.5) 
40 25 (52.1) 48  
Moderate anaemia (HCT 15 - | 
25%), n (%) 
32 (47.8) 69 
22 
(55.0) 
40 8 (16.7) 48  
Severe anaemia (HCT ≤ 
15%), n (%) 
0 (0) 69 
5 
(12.5) 
40 1 (2.1) 48  
Micro-biology and other laboratory 
results on admission 
















HIV status positive, n (%) 25 (36.2) 69 3 (7.1) 42 5 (10.4) 48 <0.0001 
Viral coinfections, n (%) 32 (46) 69 22 (52) 42 - - 0.56⫪ 
Positive blood culture, n (%) 29 (42.0) 69 0 (0) 42 0 (0) 48  
WBC count (103/uL), mean (SD) 







Neutrophil granulocytes (103/uL), 
mean (SD) 
13.7 (9.8) 57 5.2 (3) 32 4.8 (2.4) 45 <0.0001 
Plasmodium density 
(parasites/uL), geometric mean 
(SD) 
0 (0) 69 
5.9 
(5.8) 
42 0 (0) 48  
Malaria positive 
0 (0) 69 
42 
(100) 
42 0 (0) 48 <0.0001 
Chest X-Ray results        
Normal, n (%) 
9 (15.0) 69 
42 
(100) 
42 27 (56.3) 48 <0.0001 
Other infiltrate/abnormality, n 
(%) 
7 (11.7) 69 0 (0) 42 21 (43.8) 48  
Primary endpoint pneumonia, n 
(%) 
44 (73.3) 69 0 (0) 42 0 (0) 48  
Evolution during admission         
Length of admission (days): Median 
















(IQR) (2 - 6.1) (2 - 
5) 
 (2.2 - 
4.8) 
Case fatality rate (in hospital 
death), n (%) 
3 (4.4) 6 0 (0) 4 0 (0) 4 0.15 
 
HCT = hematocrit; IQR = Interquartile Range; MUAC = middle upper arm circumference; n= number of patients, SD = 
Standard Deviation; WAZ = weight-for-age Z score, Z-score cut-off point of <-2 SD and <-3 SD is classified as low 
weight for age and severe undernutrition, respectively. † P-values for continuous variables were estimated through 
analysis of variance (Kruskal-Wallis test). P-values for categorical variables used Chi Square test.⫪ P-value of the 
categorical variable was estimated through Fisher’s exact test. 
 
The “bacteria” group includes blood or pleural fluid culture-positive samples, samples PCR-positive for respiratory 
pathogens, and samples with positive leukocytosis and a dense radiographic consolidation (endpoint pneumonia) as 


















Table 2 Single etiology and mixed infection validation set predictive diagnostic results  
(A) Confusion matrices and performance specifications for models using all (219 and 151, 
respectively)  markers and 5 markers, as well as accuracy for models using 5, 10, 15, 25, 50, 100, and 
219 markers with 0%, 10% or 20% surrogates. The BvV validation set contains 19 bacteria and 13 
virus samples, and the BvVM samples 19 bacteria, 15 malaria, and 13 virus samples. (B) Confusion 
matrices and performance statistics with all (151) or only 5 markers depicted. The mixed infection 
test set contains 39 samples. All samples that contain the term “bacteria” are considered positive 
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